Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 7/20 | 0.49 |
| ▸ | CLK1 | P49759 | 4/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | F9 | P00740 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31232895 | 1.00 | HDAC1 (0.49) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL22468777 | 0.86 | LMNA (0.50) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL29570549 | 0.86 | LMNA (0.50) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL29065456 | 0.84 | BCL2L1 (0.58) | HDAC1DYRK1ASLC6A2SLC6A3KMT2A | |
| SCHEMBL31232887 | 0.83 | CLK1 (0.46) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL22468637 | 0.83 | TDP1 (0.45) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL17149292 | 0.83 | CLK1 (0.46) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL9176841 | 0.83 | CYP4F2 (0.51) | HDAC1CLK1DYRK1ATDP1DYRK1B | |
| SCHEMBL26298420 | 0.81 | HDAC1 (0.44) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 | |
| SCHEMBL15698906 | 0.80 | SLC6A2 (0.46) | HDAC1CLK1DYRK1ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | RECLUDIX PHARMA INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. | 2025-06-05 | — | — | US | disclosed |
| EP-4499656-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4463459-A1 | STAT MODULATORS AND USES THEREOF | Recludix Pharma, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023192960-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| WO-2023164680-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | RECLUDIX PHARMA, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023133336-A1 | STAT MODULATORS AND USES THEREOF | RECLUDIX PHARMA, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179103-A1 | 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS | STAT6, STAT3, STAT1 | HDAC1 168/4885CLK1 3404/4885DYRK1A 909/4885 |
| US-20250215030-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | HDAC1 227/4885CLK1 2193/4885DYRK1A 842/4885 |
| US-20260015373-A1 | STAT6 MODULATORS AND USES THEREOF | STAT6, STAT5A, STAT3 | HDAC1 136/4885CLK1 1585/4885DYRK1A 2705/4885 |
| US-20250215029-A1 | STAT MODULATORS AND USES THEREOF | STAT6, STAT3, STAT5A | HDAC1 159/4885CLK1 2081/4885DYRK1A 955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.